New Stock News | Jiangxi Biopharmaceutical Port IPO prospectus invalid

Jiangxi Biotech Research Institute Co., Ltd. (referred to as Jiangxi Bio) submitted its Hong Kong IPO prospectus on April 11, which expired after 6 months on October 11, with CICC and CMSC International as joint sponsors when submitting the application. According to the prospectus, based on data from Frost & Sullivan, Jiangxi Bio is the largest provider of human tetanus antitoxin (TAT) in China and globally, with market shares of 65.8% and 36.6% by sales in 2024. Tetanus antitoxin is a type of antiserum that neutralizes the toxin produced by the bacterium that causes tetanus, providing immediate protection and treatment to prevent and treat tetanus infections.